Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

23.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.7K
MicroRNAs01:22

MicroRNAs

3.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

3.4K
The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
3.4K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

291
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
291
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

698
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
698
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

781
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
781

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing hypertension in obstructive sleep apnea: the interplay of continuous positive airway pressure, medication and chronotherapy.

Journal of hypertension·2010
Same author

Association of interleukin-18 levels with global arterial function and early structural changes in men without cardiovascular disease.

American journal of hypertension·2010
Same author

Monocyte expression of adhesion molecules during low- and high-flux polysulfone hemodialysis and the effect of atorvastatin administration.

Blood purification·2010
Same author

The role of European national journals in education.

Revista espanola de cardiologia·2009
Same author

Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.

International journal of cardiology·2009
Same author

Is there a role for erythropoietin in cardiovascular disease?

Expert opinion on biological therapy·2009

Related Experiment Video

Updated: Dec 23, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.8K

MicroRNAs in cardiovascular disease.

Gerasimos Siasos1, Evanthia Bletsa2, Panagiota K Stampouloglou2

  • 1Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|April 20, 2020
PubMed
Summary

MicroRNAs show promise as biomarkers for cardiovascular disease (CVD) diagnosis and management. This review highlights recent data on their potential in classifying, stratifying, and guiding individualized treatment for CVD patients.

Keywords:
AtherosclerosisBiomarkersCardiovascular diseaseMicroRNAsMolecular cardiology

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.4K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.5K

Related Experiment Videos

Last Updated: Dec 23, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.8K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.4K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.5K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death globally.
  • MicroRNAs are increasingly recognized for their roles in various diseases.
  • Biomarkers are crucial for effective CVD diagnosis and patient management.

Purpose of the Study:

  • To review recent findings on microRNAs as biomarkers for cardiovascular disease.
  • To explore the potential of microRNAs in CVD classification and risk stratification.
  • To assess microRNAs' utility in guiding individualized CVD treatment strategies.

Main Methods:

  • Literature review of recent studies on microRNAs and cardiovascular disease.
  • Analysis of data concerning microRNA properties in CVD patient classification.
  • Evaluation of microRNAs for prognosis and monitoring in cardiovascular conditions.

Main Results:

  • MicroRNAs demonstrate significant potential as diagnostic and prognostic biomarkers for CVD.
  • Specific microRNAs are associated with different CVD classifications and risk levels.
  • Emerging evidence supports microRNAs in personalized CVD management and treatment guidance.

Conclusions:

  • MicroRNAs represent a promising class of novel biomarkers for cardiovascular disease.
  • Further research is warranted to fully integrate microRNAs into clinical practice for CVD.
  • MicroRNA profiling may enhance the precision of cardiovascular disease diagnosis and therapy.